Sequential topoisomerase I (topo I) and topoisomerase II (topo II) inhibitors in relapsed/refractory aggressive NHL: Results of CALGB 59906, a phase II study of doxorubicin and topotecan.

被引：0
|
作者：
Smith, SM
Johnson, JL
Niedzwiecki, D
Eder, JP
Canellos, GP
Cheson, BD
Bartlett, NL
机构：
[1] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[2] Duke Univ, Canc & Leukemia Grp B, Ctr Stat, Durham, NC USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA
[5] Washington Univ, St Louis, MO USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.2500.2500
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2500
引用
收藏
页码：685A / 686A
页数：2
相关论文
共 50 条
  • [11] Relationship between topoisomerase II alpha (TOPO IIα) and Her-2/neu expression in stage I pulmonary adenocarcinomas
    Cosar, EF
    Siziopikou, KP
    Morgan, MW
    Husain, AN
    LABORATORY INVESTIGATION, 2002, 82 (01) : 318A - 318A
  • [12] Relationship between topoisomerase II alpha (TOPO IIα) and Her-2/neu expression in stage I pulmonary adenocarcinomas
    Cosar, EF
    Siziopikou, KP
    Morgan, MW
    Husain, AN
    MODERN PATHOLOGY, 2002, 15 (01) : 318A - 318A
  • [13] Phase I/II trial of IV topotecan (TOPO) in combination with whole brain radiation therapy (WBXRT).
    Spear, MA
    Mirmiran, A
    McClay, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 120S - 120S
  • [14] Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer
    Dowlati, A
    Levitan, N
    Gordon, NH
    Hoppel, CL
    Gosky, DM
    Remick, SC
    Ingalls, ST
    Berger, SJ
    Berger, NA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 47 (02) : 141 - 148
  • [15] TOPOISOMERASE-I INHIBITORS - REVIEW OF CLINICAL-PHASE-II TRIALS OF IRINOTECAN (CPT-11) AND TOPOTECAN
    BONNETERRE, J
    BULLETIN DU CANCER, 1995, 82 (08) : 623 - 628
  • [16] Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer
    Afshin Dowlati
    Nathan Levitan
    Nahida H. Gordon
    Charles L. Hoppel
    David M. Gosky
    Scot C. Remick
    Stephen T. Ingalls
    Sossamma J. Berger
    Nathan A. Berger
    Cancer Chemotherapy and Pharmacology, 2001, 47 : 141 - 148
  • [17] Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
    R S de Jong
    N H Mulder
    D R A Uges
    D Th Sleijfer
    F J P Höppener
    H J M Groen
    P H B Willemse
    W T A van der Graaf
    E G E de Vries
    British Journal of Cancer, 1999, 79 : 882 - 887
  • [18] Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
    de Jong, RS
    Mulder, NH
    Uges, DRA
    Sleijfer, DT
    Höppener, FJP
    Groen, HJM
    Willemse, PHB
    van der Graaf, WTA
    de Vries, EGE
    BRITISH JOURNAL OF CANCER, 1999, 79 (5-6) : 882 - 887
  • [19] PHASE-I STUDY OF TOPOTECAN, A NEW TOPOISOMERASE-I INHIBITOR, IN PATIENTS WITH REFRACTORY OR RELAPSED ACUTE-LEUKEMIA
    KANTARJIAN, HM
    BERAN, M
    ELLIS, A
    ZWELLING, L
    OBRIEN, S
    CAZENAVE, L
    KOLLER, C
    RIOS, MB
    PLUNKETT, W
    KEATING, MJ
    ESTEY, EH
    BLOOD, 1993, 81 (05) : 1146 - 1151
  • [20] Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer
    Heist, Rebecca Suk
    Fain, Jerry
    Chinnasami, Bernard
    Khan, Waseem
    Molina, Julian R.
    Sequist, Lecia V.
    Temel, Jennifer S.
    Fidias, Panos
    Brainerd, Valari
    Leopold, Lance
    Lynch, Thomas J.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1637 - 1643
12345